

December 09, 2021

To  The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> Floor, Dalal Street Mumbai – 400001  <b>Code: 540222</b>	To  The Listing Department National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051  <b>Code: LAURUSLABS</b>
--	--

**Sub: Update on Investment in M/s. Immunoadoptive Cell Therapy Private Limited**

**Ref: Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 dated November 19, 2021**

Dear Sirs,

This has reference to our disclosure dated November 19, 2021 regarding the signing of an investment agreement with M/s. Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company to acquire 26.62% stake (fully diluted basis), subject to completion of conditions precedent, for a cash consideration of approximately Rs. 46.00 Crores.

In this regard, we wish to update that the Company has paid the subscription amount of Rs.27.60 Crores (Rupees Twenty-Seven Crores and Sixty Lakhs only) as “Tranche 1 Subscription Amount” today (i.e. on December 09, 2021). Along with the Company, the senior management of the Company also paid the “Tranche 1 Subscription Amount” today.

This is for your information and record.

Yours faithfully,  
**For Laurus Labs Limited**

  
**G. Venkateswar Reddy**  
Company Secretary

